

**The Health Service (Benefit) (Limited List) (Pharmaceutical  
Benefit) (Amendment No. 3) Regulations, 2021**

<i>Made</i>	1 <sup>st</sup> June, 2021
<i>Coming into operation</i>	2 <sup>nd</sup> June, 2021
<i>Laid before the States</i>	, 2021

THE COMMITTEE FOR HEALTH & SOCIAL CARE, in exercise of the powers conferred on it by sections 10 and 35 of the Health Service (Benefit) (Guernsey) Law, 1990<sup>a</sup> and section 1 of the Health Service (Benefit) (Limited Lists) Ordinance, 2004<sup>b</sup>, and all other powers enabling it in that behalf, hereby makes the following Regulations:-

**Amendment to the 2004 Regulations.**

1. In the Schedule to the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) Regulations, 2004<sup>c</sup> ("the 2004 Regulations") -

---

<sup>a</sup> Ordres en Conseil Vol. XXXII, p. 192; amended by Order in Council No. IX of 2003; No. II of 2011; No. IV of 2018; Recueil d'Ordonnances Tome XXVI, pp. 177 and 483; Ordinance Nos. XXII and XXVII of 2002; Nos. XXI and XXXIII of 2003; No. XLII of 2006; No. XLIII of 2007; No. XXII of 2015; Nos. IX and XLIV of 2016; and No. XVI of 2020. Applied with modifications by Recueil d'Ordonnances Tome XXV, p. 204; Tome XXVI, p. 484; Tome XXVII, p. 200; and Tome XXVIII, p. 1.

<sup>b</sup> Ordinance No. XIII of 2004; amended by No. XXXIV of 2013 and No. XXV of 2017.

<sup>c</sup> G.S.I. No. 9 of 2004 as amended by G.S.I. No. 42 of 2004; No's 18, 25 and 38 of 2005; No's 12, 18, 26, 36 and 46 of 2006; No's 3, 5, 6, 16, 17 and 32 of 2007; No's 11, 23, 29, 31, 47, 50 and 76 of 2008; No's 16, 35, 43, 47 and 56 of 2009; No's 5, 32, 48, 88, 91 and 99 of 2010; No's 5, 13, 19, 37, 38 and 52 of 2011; No's 5, 25, 33 and 52 of 2012; No's 5, 27, 35, 42, 68, 78 and 87 of 2013; No's 8, 11, 16, 25, 57, 69 and 99 of 2014; No's 9, 33 and 106 of 2015; No's 10, 17, 25, 31 and 49 of 2016; No's 48, 69, 78, 88 and 117 of 2017; No's 6, 9, 16, 28, 35, 40 and 43 of 2018; No's 1,


- (a) insert the entries set out in Schedule 1 to these Regulations in the appropriate places and under the appropriate headings, and
- (b) for each pharmaceutical benefit in column 3 of Schedule 2 to these Regulations listed in the Schedule to the 2004 Regulations (under the reference and heading in columns 1 and 2 of Schedule 2 to these Regulations respectively), substitute the corresponding pharmaceutical benefit in column 4 of Schedule 2 to these Regulations.

**Citation, commencement and extent.**

2. (1) These Regulations may be cited as the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) (Amendment No. 3) Regulations, 2021, and shall come into force on the 2<sup>nd</sup> day of June, 2021.

(2) These Regulations shall have effect in the Islands of Guernsey, Alderney, Herm and Jethou.

Dated this 1<sup>st</sup> day of June, 2021.



A. H. BROUARD

President of the States Committee for Health & Social Care

For and on behalf of the Committee

SCHEDULE 1

Reg. 1(a)

ENTRIES TO BE INSERTED IN THE SCHEDULE TO THE 2004 REGULATIONS

British National Formulary (BNF) Section	Heading	Pharmaceutical Benefit
1.5.3	Chronic Bowel Disorders (Immunosuppressants – Protein Kinase Inhibitors)	Tofacitinib, film-coated tablets, 5mg, 10mg (In accordance with NICE TA number 547 or any revision thereof only)
5.3	Antivirals	Raltegravir, tablets, 600mg (Initiation by publically-funded Consultant Virologist only)
8.2.4	Other immunomodulating drugs	Siponimod as Siponimod fumaric acid film-coated tablets 0.25 mg, 2 mg (In accordance with NICE TA number 656 or any revision thereof only)
10.1.3	Rheumatic Disease Suppressant (Immunosuppressants – Protein Kinase Inhibitors)	Tofacitinib, film-coated tablets, 5mg, prolonged-release tablets, 11mg (In accordance with NICE TA number 480 or any revision thereof only)
	Wound Management Products and elasticated garments	Suprasorb P Sensitive Border (all sizes in current Drug Tariff)

SCHEDULE 2

Reg. 1(b)

PHARMACEUTICAL BENEFITS TO BE SUBSTITUTED IN THE SCHEDULE TO  
THE 2004 REGULATIONS

Column 1: British National Formulary (BNF) Section	Column 2: Heading	Column 3: Current Pharmaceutical Benefit	Column 4: New Pharmaceutical Benefit
5.3	Antivirals	Emtricitabine 200mg /Tenofovir 245 mg (Initiation only by publically-funded Consultant Virologist)	Emtricitabine 200mg/Tenofovir disoproxil 245mg (AAH only and initiation only by publically- funded Consultant Virologist)
	Wound Management Products and elasticated garments	Mepilex Border 7x7.5cm, 10x12.5cm, 10x20cm, 10x30cm, 15x17.5cm and 17x20cm	Mepilex Border 7x7.5cm, 10x12.5cm, 10x20cm, 10x30cm, 15x17.5cm and 17x20cm (For complex wounds and on the recommendation of the CNS in Tissue Viability only)

## **EXPLANATORY NOTE**

*(This note is not part of the Regulations)*

These Regulations add drugs and dressings to the list of products that may be prescribed as pharmaceutical benefit and amend the permissible prescribing of two products already on that list

These Regulations come into force on the 2<sup>nd</sup> June, 2021.

